ZA200804497B - (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions - Google Patents
(Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditionsInfo
- Publication number
- ZA200804497B ZA200804497B ZA200804497A ZA200804497A ZA200804497B ZA 200804497 B ZA200804497 B ZA 200804497B ZA 200804497 A ZA200804497 A ZA 200804497A ZA 200804497 A ZA200804497 A ZA 200804497A ZA 200804497 B ZA200804497 B ZA 200804497B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrazines
- indazol
- indol
- dihydro
- conditions
- Prior art date
Links
- UMRCHZNOQHLOGW-UHFFFAOYSA-N 1,3-dihydroindol-2-one;pyrazine Chemical class C1=CN=CC=N1.C1=CC=C2NC(=O)CC2=C1 UMRCHZNOQHLOGW-UHFFFAOYSA-N 0.000 title 1
- GTHRBGRAVFPOMM-UHFFFAOYSA-N 5-pyrazin-2-yl-1h-indazole Chemical class C1=C2C=NNC2=CC=C1C1=CN=CC=N1 GTHRBGRAVFPOMM-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000000568 rho-Associated Kinases Human genes 0.000 title 1
- 108010041788 rho-Associated Kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75313605P | 2005-12-22 | 2005-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200804497B true ZA200804497B (en) | 2009-10-28 |
Family
ID=37963712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200804497A ZA200804497B (en) | 2005-12-22 | 2006-12-19 | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions |
Country Status (14)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2580108T3 (es) * | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Compuestos de isoquinolina |
| US20070135499A1 (en) * | 2005-07-11 | 2007-06-14 | Aerie Pharmaceuticals, Inc. | Hydrazide compounds |
| EP2526948A1 (en) | 2006-09-20 | 2012-11-28 | Aerie Pharmaceuticals, Inc. | RHO kinase inhibitors |
| CA2663436A1 (en) * | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| EP2299820A4 (en) * | 2008-06-18 | 2012-11-14 | Inspire Pharmaceuticals Inc | OPHTHALMOLOGICAL FORMULATION OF RHO KINASE INHIBITOR COMPOUND |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| KR101712576B1 (ko) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물 |
| PL3354650T3 (pl) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| WO2010126626A2 (en) | 2009-05-01 | 2010-11-04 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| JP5739448B2 (ja) | 2009-12-21 | 2015-06-24 | アレイ バイオファーマ、インコーポレイテッド | cFMS阻害剤としての置換N−(1H−インダゾール−4−イル)イミダゾ[1,2−a]ピリジン−3−カルボキサミド化合物 |
| WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| JP5836367B2 (ja) | 2010-05-12 | 2015-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼ阻害剤として有用な化合物 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013529643A (ja) | 2010-06-23 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用なピロロピラジン誘導体 |
| CA2832100A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| IN2014KN00943A (cg-RX-API-DMAC10.html) | 2011-09-30 | 2015-08-21 | Vertex Pharma | |
| RU2018147217A (ru) | 2011-09-30 | 2019-01-18 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CN104582795B (zh) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| ES2776199T3 (es) | 2013-03-15 | 2020-07-29 | Aerie Pharmaceuticals Inc | Conjugados de compuestos de isoquinolina y prostaglandinas |
| US9328200B2 (en) * | 2013-07-17 | 2016-05-03 | Ultrasci Discovery Llp | Branched polymeric quaternary ammonium compounds and their uses |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2017086941A1 (en) | 2015-11-17 | 2017-05-26 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| WO2018045091A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
| CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2021247690A1 (en) * | 2020-06-03 | 2021-12-09 | Glaukos Corporation | Rho kinase inhibitor releasing implants and related methods of use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0492903A1 (en) * | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma |
| JP3719609B2 (ja) * | 1995-12-21 | 2005-11-24 | アルコン ラボラトリーズ,インコーポレイテッド | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 |
| US5798380A (en) * | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| PT956865E (pt) * | 1996-08-12 | 2007-07-30 | Mitsubishi Pharma Corp | Medicamentos compreendendo inibidores da rho cinase. |
| CA2214841A1 (en) | 1997-10-31 | 1999-04-30 | Lisa Mckerracher | Rho antagonists and their use to block inhibition of neurite outgrowth |
| KR100616466B1 (ko) * | 1998-08-17 | 2006-08-29 | 센주 세이야꾸 가부시키가이샤 | 녹내장 예방/치료제 |
| AU4144400A (en) * | 1999-04-27 | 2000-11-10 | Mitsubishi Pharma Corporation | Preventives/remedies for liver diseases |
| JP3430254B2 (ja) | 2000-03-13 | 2003-07-28 | 独立行政法人産業技術総合研究所 | β−ジケトナートを有する金属錯体及びその製法、光電変換素子並びに、光化学電池 |
| ES2266171T3 (es) | 2000-03-16 | 2007-03-01 | Mitsubishi Pharma Corporation | Compuestos de amida y su uso. |
| JP4776138B2 (ja) * | 2000-03-31 | 2011-09-21 | 田辺三菱製薬株式会社 | 腎臓疾患予防・治療剤 |
| EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1465900B1 (en) | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitors |
| CA2473910C (en) | 2002-01-23 | 2011-03-15 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| AU2003281623B8 (en) | 2002-07-22 | 2009-06-11 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| CA2502583A1 (en) | 2002-09-12 | 2004-03-25 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
| WO2004084824A2 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| EP1644365A2 (en) * | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| US7390907B2 (en) * | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1830853B1 (en) * | 2004-12-27 | 2011-08-10 | Novartis AG | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases |
-
2006
- 2006-12-19 MX MX2008008328A patent/MX2008008328A/es active IP Right Grant
- 2006-12-19 ZA ZA200804497A patent/ZA200804497B/xx unknown
- 2006-12-19 US US11/612,894 patent/US7655662B2/en not_active Expired - Fee Related
- 2006-12-19 JP JP2008547727A patent/JP2009521494A/ja active Pending
- 2006-12-19 KR KR1020087015628A patent/KR20080077652A/ko not_active Ceased
- 2006-12-19 CN CNA2006800482845A patent/CN101340912A/zh active Pending
- 2006-12-19 CA CA002629342A patent/CA2629342A1/en not_active Abandoned
- 2006-12-19 BR BRPI0620463-5A patent/BRPI0620463A2/pt not_active IP Right Cessation
- 2006-12-19 RU RU2008130111/04A patent/RU2008130111A/ru unknown
- 2006-12-19 WO PCT/US2006/062307 patent/WO2007076360A1/en not_active Ceased
- 2006-12-19 EP EP06846689A patent/EP1962853A1/en not_active Withdrawn
- 2006-12-21 AR ARP060105725A patent/AR058618A1/es not_active Application Discontinuation
- 2006-12-21 TW TW095148175A patent/TW200733964A/zh unknown
- 2006-12-21 UY UY30058A patent/UY30058A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101340912A (zh) | 2009-01-07 |
| RU2008130111A (ru) | 2010-01-27 |
| MX2008008328A (es) | 2008-09-15 |
| TW200733964A (en) | 2007-09-16 |
| EP1962853A1 (en) | 2008-09-03 |
| US7655662B2 (en) | 2010-02-02 |
| WO2007076360A1 (en) | 2007-07-05 |
| CA2629342A1 (en) | 2007-07-05 |
| KR20080077652A (ko) | 2008-08-25 |
| US20070149548A1 (en) | 2007-06-28 |
| JP2009521494A (ja) | 2009-06-04 |
| AR058618A1 (es) | 2008-02-13 |
| BRPI0620463A2 (pt) | 2011-11-16 |
| WO2007076360A8 (en) | 2007-12-06 |
| UY30058A1 (es) | 2007-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| SI1984357T1 (sl) | Spojine 2,4-pirimidindiamina za zdravljenje ali preventivo avtoimunih bolezni | |
| TWI372752B (en) | Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same | |
| LT1965816T (lt) | Farmacinės kompozicijos ir metodai, skirti su oksalatu susijusių ligų gydymui arba prevencijai | |
| IL182837A0 (en) | Methods, assays and compositions for treating retinol-related diseases | |
| IL190913B (en) | Preparations for the treatment of sweating disorders | |
| IL180342A0 (en) | Compositions and methods for treating eye disorders and conditions | |
| IL184456A0 (en) | Dosage form for treating gastrointestinal disorders | |
| IL185242A0 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| PL2057153T3 (pl) | POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY | |
| HUE059861T2 (hu) | N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra | |
| ZA200809659B (en) | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | |
| PL2803366T3 (pl) | Kompozycje do leczenia lub profilaktyki choroby związanej ze szczawianem | |
| WO2009071689A3 (de) | 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
| IL191237A0 (en) | Compositions and methods for treating thrombocytopenia | |
| ZA200804951B (en) | Compositions and methods for treating CNS disorders | |
| EP1959931A4 (en) | COMPOSITIONS AND METHODS FOR THE DERMAL TREATMENT OF PAIN | |
| GB0725227D0 (en) | Thermotherapy apparatus | |
| IL186748A0 (en) | 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility | |
| ZA200707472B (en) | Diosmetin derivatives for the treatment and prevention of thrombotic pathologies | |
| EP2025667A4 (en) | 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS | |
| PL2059503T3 (pl) | Pochodne aminopirazolu, sposób ich wytwarzania oraz kompozycja do zapobiegania lub leczenia chorób niedokrwiennych zawierająca takie pochodne | |
| PL1841433T3 (pl) | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego | |
| GB0605715D0 (en) | Treatment of laminitis | |
| EP1890711A4 (en) | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES |